文献速递冠心病血脂与心血管预防

稳定性心绞痛患者的评估与管理:超越缺血范式

Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该综述指出冠心病是慢性全身性疾病,生活方式与危险因素干预及药物治疗可延缓动脉粥样硬化进展并降低斑块破裂时的血栓风险;随着预防与药物治疗有效性提升,血运重建作用已缩小,主要限于无法耐受的心绞痛、严重左室收缩功能障碍或高危冠脉解剖亚组。

要点

  • 优化生活方式、危险因素控制与药物治疗是稳定性冠心病管理的基石。
  • 血运重建适用于无法耐受的心绞痛、严重左室收缩功能障碍或高危冠脉解剖者。
  • 应合理分配资源以加强预防,而非过度依赖血运重建。

核心结论

  • 稳定性冠心病管理应以预防和药物治疗为基础,血运重建仅限特定亚组。

研究设计与样本

  • 本文为JACC state-of-the-art综述,回顾支持药物治疗与血运重建的科学证据。

主要发现

  • 生活方式与危险因素干预及药物治疗可减缓动脉粥样硬化进展并降低斑块破裂时的血栓风险。
  • 随预防与药物治疗有效性提升,冠脉血运重建的作用已减小。
  • 血运重建主要限于无法耐受的心绞痛、严重左室收缩功能障碍或高危冠脉解剖患者。

临床怎么用

  • 对稳定性心绞痛患者应优先强化生活方式、危险因素控制与药物治疗。
  • 仅在无法耐受的心绞痛、严重左室收缩功能障碍或高危冠脉解剖时考虑血运重建。
  • 公共卫生政策应合理分配资源以加强冠心病预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronary heart disease is a chronic, systemic disease with a wide range of associated symptoms, clinical outcomes, and health care expenditure. Adverse events from coronary heart disease can be mitigated or avoided with lifestyle and risk factor modifications, and medical therapy. These measures are effective in slowing the progression of atherosclerotic disease and in reducing the risk of thrombosis in the setting of plaque disruptions. With increasing effectiveness of prevention and medical therapy, the role of coronary artery revascularization has decreased and is largely confined to subgroups of patients with unacceptable angina, severe left ventricular systolic dysfunction, or high-risk coronary anatomy. There is a compelling need to allocate resources appropriately to improve prevention. Herein, we review the scientific evidence in support of medical therapy and revascularization for the management of patients with stable coronary heart disease and discuss implications for the evaluation of patients with stable angina and public policy.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ferraro R, Latina JM, Alfaddagh A, et al. Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020. PMID: 33153586. doi:10.1016/j.jacc.2020.08.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。